LGND — Ligand Pharmaceuticals Incorporated

Summary of Ligand's Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $52 million, up 14% year-over-year.
• Royalty Revenue: $43 million, a significant increase of 56% compared to Q1 2025.
• Adjusted EPS: $1.63, reflecting a 23% growth year-over-year.
• Cash Position: Approximately $780 million in cash and investments, plus $200 million in undrawn credit capacity, totaling nearly $1 billion available for future investments.

2. Strategic Updates and Business Highlights:

• Ligand is transitioning to a pure royalty aggregation model, having divested two platform businesses and reduced operational expenses from $90 million to $40 million.
• The company has expanded its commercial assets from 7 to 15 and closed 18 deals in the last three years, enhancing its late-stage clinical pipeline.
• Key growth drivers include Filspari, Ohtuvayre, and Qarziba, with Filspari becoming the largest royalty asset following its FDA approval for FSGS.
• The acquisition of XOMA Royalty Corporation, expected to close in Q3 2026, will add over 120 assets, including seven marketed products, and is projected to be immediately accretive to earnings.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Total revenue expected between $270 million and $310 million, with royalty revenue projected at $225 million to $250 million.
• Adjusted EPS Guidance: Expected to be between $8.50 and $9.50, with an anticipated $0.50 increase in EPS from the XOMA acquisition in 2026 and $1.50 in 2027.
• The company expects to generate approximately $300 million in operating cash flow and plans to invest $150 million to $250 million annually in new royalty opportunities.

4. Bad News, Challenges, or Points of Concern:

• The company reported a GAAP diluted loss per share of $0.67, compared to a loss of $2.21 in the prior year, primarily due to fair value adjustments on equity holdings.
• Non-operating expenses increased significantly to $41.6 million, driven by changes in the fair value of investments, which could indicate volatility in asset valuations.
• The approval of Filspari was delayed by a quarter, which may impact near-term revenue realization despite long-term growth potential.

5. Notable Q&A Insights:

• Management emphasized that while they do not need additional deals to sustain over 20% growth, they will continue to pursue new investments to compound growth.
• The integration of XOMA is expected to yield high synergies, potentially approaching 100%, and will not significantly impact near-term deal activity.
• Ligand is committed to managing its existing portfolio actively, with plans to out-license or partner underperforming assets as needed.
• The company is optimistic about the commercial potential of Filspari and other pipeline assets, with significant growth expected from both existing and newly acquired products.

Overall, Ligand's Q1 2026 performance reflects strong revenue growth driven by strategic shifts towards royalty aggregation, with a positive outlook bolstered by the upcoming XOMA acquisition and the successful launch of key products. However, challenges remain in terms of GAAP losses and market volatility.